As expected, the percentages of CD19+ B cells were also significantly reduced at both collection time points in patients treated with S1P receptor modulators (P < 0.0001), RTX (P < 0.0001), and OCR (P < 0.0001) compared with patients with untreated MS (Supplemental Figure 1D). This evidence concerns the gene CD19 and myeloid sarcoma.